Renal fibrosis and proteomics: Current knowledge and still key open questions for proteomic investigation

Journal of Proteomics

Volumn 74, Issue 10, 2011, Pages 1855-1870

  Prunotto, Marco ^a,c   Ghiggeri, GianMarco ^a   Bruschi, Maurizio ^a   Gabbiani, Giulio ^b   Lescuyer, Pierre ^c   Hocher, Berthold ^d   Chaykovska, Lyubov ^d,e   Berrera, Marco ^e   Moll, Solange ^c  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

CKD; Drug discovery; Fibrosis; Kidney; Myofibroblast; Proteomics

Indexed keywords

CYCLOSPORIN A; SMOOTH MUSCLE ACTIN; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1;

AFFINITY CHROMATOGRAPHY; CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; DENDRITIC CELL; EPITHELIUM CELL; FIBROGENESIS; GLOMERULONEPHRITIS; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MYOFIBROBLAST; NEPHRECTOMY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANOXIA; BLOOD GLUCOSE; CYCLOSPORINE; DIABETIC NEPHROPATHIES; FIBROSIS; GLOMERULONEPHRITIS; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; PROTEOMICS; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA;

EID: 80052036923     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.05.031     Document Type: Review

References (108)

1. Coresh J., Selvin E., Stevens L.A., Manzi J., Kusek J.W., Eggers P., et al. Prevalence of chronic kidney disease in the United States. Jama 2007, 298:2038-2047.
2. Lameire N., Jager K., Van Biesen W., de Bacquer D., Vanholder R. Chronic kidney disease: a European perspective. Kidney Int Suppl 2005, S30-S38.
3. Ruggenenti P., Perticucci E., Cravedi P., Gambara V., Costantini M., Sharma S.K., et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008, 19:1213-1224.
4. Rosolowsky E.T., Skupien J., Smiles A.M., Niewczas M., Roshan B., Stanton R., et al. Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol 2011, 22:545-553.
5. Risdon R.A., Sloper J.C., De Wardener H.E. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968, 2:363-366.
6. Schainuck L.I., Striker G.E., Cutler R.E., Benditt E.P. Structural-functional correlations in renal disease. II. The correlations. Hum Pathol 1970, 1:631-641.
7. Harris R.C., Neilson E.G. Toward a unified theory of renal progression. Annu Rev Med 2006, 57:365-380.
8. Farris A.B., Adams C.D., Brousaides N., Della Pelle P.A., Collins A.B., Moradi E., et al. Morphometric and visual evaluation of fibrosis in renal biopsies. J Am Soc Nephrol 2010, 22:176-186.
9. Alexakis C., Maxwell P., Bou-Gharios G. Organ-specific collagen expression: implications for renal disease. Nephron Exp Nephrol 2006, 102:e71-e75.
10. Eddy A.A. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996, 7:2495-2508.
11. Zeisberg M., Neilson E.G. Mechanisms of Tubulointerstitial Fibrosis. J Am Soc Nephrol 2010, 21(11):1819-1834.
12. Neilson E.G., McCafferty E., Feldman A., Clayman M.D., Zakheim B., Korngold R. Spontaneous interstitial nephritis in kdkd mice. I. An experimental model of autoimmune renal disease. J Immunol 1984, 133:2560-2565.
13. Tomasek J.J., Gabbiani G., Hinz B., Chaponnier C., Brown R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002, 3:349-363.
14. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J Pathol 2008, 214:199-210.
15. Zeisberg M., Duffield J.S. Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol 2010, 21:1247-1253.
16. Kalluri R., Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003, 112:1776-1784.
17. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010, 21:212-222.
18. Humphreys B.D., Lin S.L., Kobayashi A., Hudson T.E., Nowlin B.T., Bonventre J.V., et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2009, 176:85-97.
19. Chase L.G., Ulloa-Montoya F., Kidder B.L., Verfaillie C.M. Islet-derived fibroblast-like cells are not derived via epithelial-mesenchymal transition from Pdx-1 or insulin-positive cells. Diabetes 2007, 56:3-7.
20. Yang L., Besschetnova T.Y., Brooks C.R., Shah J.V., Bonventre J.V. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010, 16:535-543. 1p following 143.
21. Becker G.J., Perkovic V., Hewitson T.D. Pharmacological intervention in renal fibrosis and vascular sclerosis. J Nephrol 2001, 14:332-339.
22. Hewitson T.D., Becker G.J. Interstitial myofibroblasts in IgA glomerulonephritis. Am J Nephrol 1995, 15:111-117.
23. Alpers C.E., Hudkins K.L., Gown A.M., Johnson R.J. Enhanced expression of "muscle-specific" actin in glomerulonephritis. Kidney Int 1992, 41:1134-1142.
24. Darby I.A., Hewitson T.D. Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol 2007, 257:143-179.
25. Malmstrom J., Lindberg H., Lindberg C., Bratt C., Wieslander E., Delander E.L., et al. Transforming growth factor-beta 1 specifically induce proteins involved in the myofibroblast contractile apparatus. Mol Cell Proteomics 2004, 3:466-477.
26. Kang J.H., Cho H.J., Lee I.S., Kim M., Lee I.K., Chang Y.C. Comparative proteome analysis of TGF-beta1-induced fibrosis processes in normal rat kidney interstitial fibroblast cells in response to ascofuranone. Proteomics 2009, 9:4445-4456.
27. Magae J., Hayasaki J., Matsuda Y., Hotta M., Hosokawa T., Suzuki S., et al. Antitumor and antimetastatic activity of an antibiotic, ascofuranone, and activation of phagocytes. J Antibiot (Tokyo) 1988, 41:959-965.
28. Chen Y.X., Li Y., Wang W.M., Zhang W., Chen X.N., Xie Y.Y., et al. Phosphoproteomic study of human tubular epithelial cell in response to transforming growth factor-beta-1-induced epithelial-to-mesenchymal transition. Am J Nephrol 2010, 31:24-35.
29. System URD USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases 2003, National Institute of Health Bethesda, MD.
30. Valmadrid C.T., Klein R., Moss S.E., Klein B.E. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000, 160:1093-1100.
31. Fioretto P., Steffes M.W., Sutherland D.E., Goetz F.C., Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:69-75.
32. Ramachandra Rao S.P., Wassell R., Shaw M.A., Sharma K. Profiling of human mesangial cell subproteomes reveals a role for calmodulin in glucose uptake. Am J Physiol Renal Physiol 2007, 292:F1182-F1189.
33. Li Z., Zhang H., Dong X., Burczynski F.J., Choy P., Yang F., et al. Proteomic profile of primary isolated rat mesangial cells in high-glucose culture condition and decreased expression of PSMA6 in renal cortex of diabetic rats. Biochem Cell Biol 2010, 88:635-648.
34. Hwang J.C., Chang L.C., Lin Y.F., Shui H.A., Chen J.S. Effects of fungal statins on high-glucose-induced mouse mesangial cell hypocontractility may involve filamentous actin, t-complex polypeptide 1 subunit beta, and glucose regulated protein 78. Transl Res 2010, 156:80-90.
35. Doublier S., Musante L., Lupia E., Candiano G., Spatola T., Caridi G., et al. Direct effect of plasma permeability factors from patients with idiopatic FSGS on nephrin and podocin expression in human podocytes. Int J Mol Med 2005, 16:49-58.
36. Shi S.F., Wang S.X., Zhang Y.K., Zhao M.H., Zou W.Z. Ultrastructural features and expression of cytoskeleton proteins of podocyte from patients with minimal change disease and focal segmental glomerulosclerosis. Ren Fail 2008, 30:477-483.
37. Phillips A.O., Steadman R., Morrisey K., Martin J., Eynstone L., Williams J.D. Exposure of human renal proximal tubular cells to glucose leads to accumulation of type IV collagen and fibronectin by decreased degradation. Kidney Int 1997, 52:973-984.
38. Sharma K., Ziyadeh F.N. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995, 44:1139-1146.
39. Ziyadeh F.N. Renal tubular basement membrane and collagen type IV in diabetes mellitus. Kidney Int 1993, 43:114-120.
40. Karamessinis P.M., Tzinia A.K., Kitsiou P.V., Stetler-Stevenson W.G., Michael A.F., Fan W.W., et al. Proximal tubular epithelial cell integrins respond to high glucose by altered cell-matrix interactions and differentially regulate matrixin expression. Lab Invest 2002, 82:1081-1093.
41. So E.-J., Kim H.-J., Kim C.-W. Proteomic analysis of human proximal tubular cells exposed to high glucose concentrations. PROTEOMICS - Clinical Applications 2008, 2:1118-1126.
42. Schordan S., Schordan E., Endlich N., Lindenmeyer M.T., Meyer-Schwesinger C., Meyer T.N., et al. Alterations of the podocyte proteome in response to high glucose concentrations. Proteomics 2009, 9:4519-4528.
43. Terrier B., Degand N., Guilpain P., Servettaz A., Guillevin L., Mouthon L. Alpha-enolase: a target of antibodies in infectious and autoimmune diseases. Autoimmun Rev 2007, 6:176-182.
44. Wakui H., Imai H., Komatsuda A., Miura A.B. Circulating antibodies against alpha-enolase in patients with primary membranous nephropathy (MN). Clin Exp Immunol 1999, 118:445-450.
45. Schreiber B.D., Hughes M.L., Groggel G.C. Insulin-like growth factor-1 stimulates production of mesangial cell matrix components. Clin Nephrol 1995, 43:368-374.
46. Tamaroglio T.A., Lo C.S. Regulation of fibronectin by insulin-like growth factor-I in cultured rat thoracic aortic smooth muscle cells and glomerular mesangial cells. Exp Cell Res 1994, 215:338-346.
47. Lee D.Y., Park S.K., Kim J.S. Insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children with nephrotic syndrome. J Clin Endocrinol Metab 1996, 81:1856-1860.
48. Pricci F., Pugliese G., Romano G., Romeo G., Locuratolo N., Pugliese F., et al. Insulin-like growth factors I and II stimulate extracellular matrix production in human glomerular mesangial cells. Comparison with transforming growth factor-beta. Endocrinology 1996, 137:879-885.
49. Matsumoto T., Hess S., Kajiyama H., Sakairi T., Saleem M.A., Mathieson P.W., et al. Proteomic analysis identifies insulin-like growth factor-binding protein-related protein-1 as a podocyte product. Am J Physiol Renal Physiol 2010, 299:F776-F784.
50. Coward R.J., Welsh G.I., Yang J., Tasman C., Lennon R., Koziell A., et al. The human glomerular podocyte is a novel target for insulin action. Diabetes 2005, 54:3095-3102.
51. Welsh G.I., Hale L.J., Eremina V., Jeansson M., Maezawa Y., Lennon R., et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 2010, 12:329-340.
52. Mann M. Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol 2006, 7:952-958.
53. Choi Y.J., Chakraborty S., Nguyen V., Nguyen C., Kim B.K., Shim S.I., et al. Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: altered expression of vascular endothelial growth factor. Human pathology 2000, 31:1491-1497.
54. Norman J.T., Clark I.M., Garcia P.L. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000, 58:2351-2366.
55. Norman J.T., Orphanides C., Garcia P., Fine L.G. Hypoxia-induced changes in extracellular matrix metabolism in renal cells. Exprimental nephrology 1999, 7:463-469.
56. Manotham K., Tanaka T., Matsumoto M., Ohse T., Inagi R., Miyata T., et al. Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int 2004, 65:871-880.
57. Boraldi F., Annovi G., Carraro F., Naldini A., Tiozzo R., Sommer P., et al. Hypoxia influences the cellular cross-talk of human dermal fibroblasts. A proteomic approach. Biochim Biophys Acta 2007, 1774:1402-1413.
58. Shakib K., Norman J.T., Fine L.G., Brown L.R., Godovac-Zimmermann J. Proteomics profiling of nuclear proteins for kidney fibroblasts suggests hypoxia, meiosis, and cancer may meet in the nucleus. Proteomics 2005, 5:2819-2838.
59. Hoang V.M., Foulk R., Clauser K., Burlingame A., Gibson B.W., Fisher S.J. Functional proteomics: examining the effects of hypoxia on the cytotrophoblast protein repertoire. Biochemistry 2001, 40:4077-4086.
60. Rao U.J., Denslow N.D., Block E.R. Hypoxia induces the synthesis of tropomyosin in cultured porcine pulmonary artery endothelial cells. Am J Physiol 1994, 267:L271-L281.
61. Borel J.F., Feurer C., Gubler H.U., Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976, 6:468-475.
62. Bennett W.M., Burdmann E.A., Andoh T.F., Houghton D.C., Lindsley J., Elzinga L.W. Nephrotoxicity of immunosuppressive drugs. Nephrol Dial Transplant 1994, 9 Suppl 4:141-145.
63. English J., Evan A., Houghton D.C., Bennett W.M. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987, 44:135-141.
64. Mihatsch M.J., Thiel G., Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988, 20:759-771.
65. Ito H., Kasagi N., Shomori K., Osaki M., Adachi H. Apoptosis in the human allografted kidney. Analysis by terminal deoxynucleotidyl transferase-mediated DUTP-botin nick end labeling. Transplantation 1995, 60:794-798.
66. Ortiz A., Lorz C., Catalan M., Ortiz A., Coca S., Egido J. Cyclosporine A induces apoptosis in murine tubular epithelial cells: role of caspases. Kidney Int Suppl 1998, 68:S25-S29.
67. Healy E., Dempsey M., Lally C., Ryan M.P. Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line. Kidney Int 1998, 54:1955-1966.
68. Hortelano S., Castilla M., Torres A.M., Tejedor A., Bosca L. Potentiation by nitric oxide of cyclosporin A and FK506-induced apoptosis in renal proximal tubule cells. J Am Soc Nephrol 2000, 11:2315-2323.
69. Justo P., Lorz C., Sanz A., Egido J., Ortiz A. Intracellular mechanisms of cyclosporin A-induced tubular cell apoptosis. J Am Soc Nephrol 2003, 14:3072-3080.
70. Puigmule M., Lopez-Hellin J., Sune G., Tornavaca O., Camano S., Tejedor A., et al. Differential proteomic analysis of cyclosporine A-induced toxicity in renal proximal tubule cells. Nephrol Dial Transplant 2009, 24:2672-2686.
71. Jung J.Y., Kang G.C., Jeong Y.J., Kim S.H., Kwak Y.G., Kim W.J. Proteomic analysis in cyclosporin A-induced overgrowth of human gingival fibroblasts. Biol Pharm Bull 2009, 32:1480-1485.
72. Abrass C.K. Lipid metabolism and renal disease. Contrib Nephrol 2006, 151:106-121.
73. Mishra R., Simonson M.S. Oleate induces a myofibroblast-like phenotype in mesangial cells. Arterioscler Thromb Vasc Biol 2008, 28:541-547.
74. Benigni A., Zoja C., Remuzzi G. The renal toxicity of sustained glomerular protein traffic. Lab Invest 1995, 73:461-468.
75. Zoja C., Morigi M., Figliuzzi M., Bruzzi I., Oldroyd S., Benigni A., et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 1995, 26:934-941.
76. Burton C.J., Combe C., Walls J., Harris K.P. Secretion of chemokines and cytokines by human tubular epithelial cells in response to proteins. Nephrol Dial Transplant 1999, 14:2628-2633.
77. Zoja C., Donadelli R., Colleoni S., Figliuzzi M., Bonazzola S., Morigi M., et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int 1998, 53:1608-1615.
78. Eleni Giannakis C.S.S., Tim D Hewitson, Wee-Ming Boon, Macris Mary, Reeve Shane, Lawrence Josie, et al. Aberrant protein expression in plasma and kidney tissue during experimental obstructive nephropathy. Proteomics Clin Appl 2009, 3:1211-1224.
79. Xu B.J., Shyr Y., Liang X., Ma L.J., Donnert E.M., Roberts J.D., et al. Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J Am Soc Nephrol 2005, 16:2967-2975.
80. Schanstra J.P., Bachvarova M., Neau E., Bascands J.L., Bachvarov D. Gene expression profiling in the remnant kidney model of wild type and kinin B1 and B2 receptor knockout mice. Kidney Int 2007, 72:442-454.
81. Vegvari A., Marko-Varga G. Clinical protein science and bioanalytical mass spectrometry with an emphasis on lung cancer. Chem Rev 2010, 110:3278-3298.
82. Sharma K., McCue P., Dunn S.R. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 2003, 284:F1138-F1144.
83. Barati M.T., Merchant M.L., Kain A.B., Jevans A.W., McLeish K.R., Klein J.B. Proteomic analysis defines altered cellular redox pathways and advanced glycation end-product metabolism in glomeruli of db/db diabetic mice. American journal of physiology 2007, 293:F1157-F1165.
84. Block C, Differential proteomic analysis of isolated glomeruli from two murine nephropathy models at early stages of glomerulosclerosis, in: Institute of Veterinary Pathology - General Pathology and Pathological Anatomy, vol. Ph.D. in Veterinary Medicine, Ludwig-Maximilians-University Munich, Munich, 2007.
85. Prunotto M., Carnevali M.L., Candiano G., Murtas C., Bruschi M., Corradini E., et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 2011, 21:507-519.
86. Yoshida Y., Miyazaki K., Kamiie J., Sato M., Okuizumi S., Kenmochi A., et al. Two-dimensional electrophoretic profiling of normal human kidney glomerulus proteome and construction of an extensible markup language (XML)-based database. Proteomics 2005, 5:1083-1096.
87. Yamamoto T. Proteomics database in chronic kidney disease. Adv Chronic Kidney Dis 2010, 17:487-492.
88. Sethi S., Gamez J.D., Vrana J.A., Theis J.D., Bergen H.R., Zipfel P.F., et al. Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int 2009, 75:952-960.
89. Kaneshiro N., Xiang Y., Nagai K., Kurokawa M.S., Okamoto K., Arito M., et al. Comprehensive analysis of short peptides in sera from patients with IgA nephropathy. Rapid Commun Mass Spectrom 2009, 23:3720-3728.
90. Hellin J.L., Bech-Serra J.J., Moctezuma E.L., Chocron S., Santin S., Madrid A., et al. Very low-molecular-mass fragments of albumin in the plasma of patients with focal segmental glomerulosclerosis. Am J Kidney Dis 2009, 54:871-880.
91. Thongboonkerd V. Biomarker discovery in glomerular diseases using urinary proteomics. Proteomics Clin Appl 2008, 2:1413-1421.
92. Nakorchevsky A., Hewel J.A., Kurian S.M., Mondala T.S., Campbell D., Head S.R., et al. Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies. J Am Soc Nephrol 2010, 21:362-373.
93. Solez K., Colvin R.B., Racusen L.C., Sis B., Halloran P.F., Birk P.E., et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007, 7:518-526.
94. Benigni A., Remuzzi G. Treatment of chronic proteinuric kidney disease: what next?. Hypertension 2009, 54:29-31.
95. Ju W., Eichinger F., Bitzer M., Oh J., McWeeney S., Berthier C.C., et al. Renal gene and protein expression signatures for prediction of kidney disease progression. Am J Pathol 2009, 174:2073-2085.
96. Schmid H., Cohen C.D., Henger A., Schlondorff D., Kretzler M. Gene expression analysis in renal biopsies. Nephrol Dial Transplant 2004, 19:1347-1351.
97. Wu L., Felton J.S., Wu K.J. Applying imaging ToF-SIMS and PCA in differentiation of tissue types. Methods Mol Biol 2010, 656:267-281.
98. Sjövalla P. JB, Belazib D., Stenvinkelc P., Lindholmc B., Lausmaaa J., Schallingb M. TOF-SIMS analysis of adipose tissue from patients with chronic kidney disease. Applied Surface Science 2008, 255:1177-1180.
99. Gharaee-Kermani M., Gyetko M.R., Hu B., Phan S.H. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy. Pharmaceutical research 2007, 24:819-841.
100. Selman M., Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respiratory research 2002, 3:3.
101. Harsha HC, Pandey A. Phosphoproteomics in cancer. Mol Oncol 4:482-95.
102. Adachi J., Kumar C., Zhang Y., Olsen J.V., Mann M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol 2006, 7:R80.
103. Anderson N.G., Anderson N.L., Tollaksen S.L. Proteins of human urine. I. Concentration and analysis by two-dimensional electrophoresis. Clin Chem 1979, 25:1199-1210.
104. Thongboonkerd V., McLeish K.R., Arthur J.M., Klein J.B. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int 2002, 62:1461-1469.
105. Candiano G., Santucci L., Petretto A., Bruschi M., Dimuccio V., Urbani A., et al. 2D-electrophoresis and the urine proteome map: where do we stand?. J Proteomics 2010, 73:829-844.
106. Thongboonkerd V. Current status of renal and urinary proteomics: ready for routine clinical application?. Nephrol Dial Transplant 2009, 25:11-16.
107. Prunotto M., Ghiggeri G.M., Candiano G., Lescuyer P., Hochstrasser D., Moll S. Urinary proteomics and drug discovery in chronic kidney disease: a new perspective. J Proteome Res 2011, 10:126-132.
108. Chen S., Kasama Y., Lee J.S., Jim B., Marin M., Ziyadeh F.N. Podocyte-derived vascular endothelial growth factor mediates the stimulation of alpha3(IV) collagen production by transforming growth factor-beta1 in mouse podocytes. Diabetes 2004, 53:2939-2949.